Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Devon Conway

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Journal of the History of the Neurosciences|January 22, 2011
The stepping test: a step back in historyChristian Grommes, Devon Conway
Current Neurology and Neuroscience Reports|June 16, 2010
Emerging oral therapies in multiple sclerosisDevon Conway, Jeffrey A Cohen
The Lancet. Neurology|February 23, 2010
Combination therapy in multiple sclerosisDevon Conway, Jeffrey A Cohen
Multiple Sclerosis Journal - Experimental, Translational and Clinical|October 28, 2020
Effect of tobacco use on disease activity and DMT discontinuation in multiple sclerosis patients treated with dimethyl fumarate or fingolimodCarrie M Hersh, Haleigh Harris, Malissa Ayers, et al.
Multiple Sclerosis and Related Disorders|March 10, 2019
Changes in patient-reported outcomes between continuers and discontinuers of disease modifying therapy in patients with multiple sclerosis over age 60Le H Hua, Haleigh Harris, Devon Conway, et al.
Neurology. Clinical Practice|January 29, 2021
Effect of switching from natalizumab to moderate- vs high-efficacy DMT in clinical practiceCarrie M Hersh, Haleigh Harris, Devon Conway, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 8, 2021
Vascular comorbidity is associated with lower brain volumes and lower neuroperformance in a large multiple sclerosis cohortKathryn C Fitzgerald, Anne Damian, Devon Conway, et al.
Journal of Neurology|April 10, 2020
Disease activity outcomes with different washout periods after switching from natalizumab to an alternative disease-modifying therapyLe H Hua, Haleigh Harris, Devon Conway, et al.
Current Treatment Options in Cardiovascular Medicine|February 8, 2012
Chronic cerebrospinal venous insufficiency as a cause of multiple sclerosis: controversy and realityClaudiu I Diaconu, Devon Conway, Robert J Fox, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 14, 2026
Long-term follow-up of patients with multiple sclerosis over age 60: Comparing clinical and radiological outcomes in disease-modifying therapy continuers and discontinuersDaniel R Orme, Eric Matesen, Devon Conway, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Journal of the History of the Neurosciences|January 22, 2011
The stepping test: a step back in historyChristian Grommes, Devon Conway
Current Neurology and Neuroscience Reports|June 16, 2010
Emerging oral therapies in multiple sclerosisDevon Conway, Jeffrey A Cohen
The Lancet. Neurology|February 23, 2010
Combination therapy in multiple sclerosisDevon Conway, Jeffrey A Cohen
Multiple Sclerosis Journal - Experimental, Translational and Clinical|October 28, 2020
Effect of tobacco use on disease activity and DMT discontinuation in multiple sclerosis patients treated with dimethyl fumarate or fingolimodCarrie M Hersh, Haleigh Harris, Malissa Ayers, et al.
Multiple Sclerosis and Related Disorders|March 10, 2019
Changes in patient-reported outcomes between continuers and discontinuers of disease modifying therapy in patients with multiple sclerosis over age 60Le H Hua, Haleigh Harris, Devon Conway, et al.
Neurology. Clinical Practice|January 29, 2021
Effect of switching from natalizumab to moderate- vs high-efficacy DMT in clinical practiceCarrie M Hersh, Haleigh Harris, Devon Conway, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 8, 2021
Vascular comorbidity is associated with lower brain volumes and lower neuroperformance in a large multiple sclerosis cohortKathryn C Fitzgerald, Anne Damian, Devon Conway, et al.
Journal of Neurology|April 10, 2020
Disease activity outcomes with different washout periods after switching from natalizumab to an alternative disease-modifying therapyLe H Hua, Haleigh Harris, Devon Conway, et al.
Current Treatment Options in Cardiovascular Medicine|February 8, 2012
Chronic cerebrospinal venous insufficiency as a cause of multiple sclerosis: controversy and realityClaudiu I Diaconu, Devon Conway, Robert J Fox, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 14, 2026
Long-term follow-up of patients with multiple sclerosis over age 60: Comparing clinical and radiological outcomes in disease-modifying therapy continuers and discontinuersDaniel R Orme, Eric Matesen, Devon Conway, et al.
Pageof 2